The U.S. Food and Drug Administration (FDA) has issued a "safe to proceed" letter to Revolution Medicines, Inc., approving the initiation of an expanded access program for its investigational drug Daraxonrasib for the treatment of pancreatic cancer patients.

Obtaining this letter means that Revolution Medicines can begin providing this experimental treatment to eligible pancreatic cancer patients. The expanded access program aims to make promising investigational therapies available to patients who have not yet participated in clinical trials. Daraxonrasib is a targeted therapy drug developed by Revolution Medicines, and the approval of this expanded access program will offer new treatment options for pancreatic cancer patients. This development marks an important step forward in the clinical development of this medication.